← Back to Screener
Vaxcyte, Inc. Common Stock (PCVX)
Price$62.20
Favorite Metrics
Price vs S&P 500 (26W)44.39%
Price vs S&P 500 (4W)5.54%
Market Capitalization$8.70B
All Metrics
Book Value / Share (Quarterly)$20.49
P/TBV (Annual)4.92x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-5.44
Price vs S&P 500 (YTD)28.37%
EPS (TTM)$-5.63
10-Day Avg Trading Volume1.24M
EPS Excl Extra (TTM)$-5.63
EPS (Annual)$-5.63
ROI (Annual)-28.55%
Cash / Share (Quarterly)$11.91
ROA (Last FY)-25.53%
EBITD / Share (TTM)$-6.39
ROE (5Y Avg)-26.74%
Cash Flow / Share (Annual)$-5.44
P/B Ratio3.24x
P/B Ratio (Quarterly)2.25x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-41.28x
ROA (TTM)-23.85%
EPS Incl Extra (Annual)$-5.63
Current Ratio (Annual)7.91x
Quick Ratio (Quarterly)7.59x
3-Month Avg Trading Volume1.36M
52-Week Price Return88.67%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$14.95
52-Week High$65.00
EPS Excl Extra (Annual)$-5.63
CapEx CAGR (5Y)117.89%
Tangible BV CAGR (5Y)98.51%
26-Week Price Return48.38%
Quick Ratio (Annual)7.69x
13-Week Price Return31.87%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.91x
Enterprise Value$8,526.026
Book Value / Share Growth (5Y)24.80%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$11.91
3-Month Return Std Dev44.63%
Net Income / Employee (TTM)$-2
ROE (Last FY)-28.55%
Net Interest Coverage (Annual)-35.22x
EPS Basic Excl Extra (Annual)$-5.63
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-5.63
ROI (TTM)-25.88%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$12.00
Price vs S&P 500 (52W)58.84%
Year-to-Date Return31.01%
5-Day Price Return-2.01%
EPS Normalized (Annual)$-5.63
ROA (5Y Avg)-24.08%
Month-to-Date Return4.03%
Cash Flow / Share (TTM)$-3.25
EBITD / Share (Annual)$-6.39
LT Debt / Equity (Annual)0.01x
ROI (5Y Avg)-26.74%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-5.63
P/TBV (Quarterly)3.35x
P/B Ratio (Annual)2.25x
Book Value / Share (Annual)$20.49
Price vs S&P 500 (13W)31.18%
Beta1.41x
Revenue / Share (TTM)$0.00
ROE (TTM)-25.88%
52-Week Low$28.09
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.31
4.29
4.29
4.29
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PCVXVaxcyte, Inc. Common Stock | — | — | — | — | $62.20 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Vaxcyte is a clinical-stage biopharmaceutical company developing novel vaccines against bacterial infections, including pneumococcal disease, Group A Streptococcus, and Shigella. The company leverages its proprietary XpressCF cell-free protein synthesis platform to design advanced conjugate and protein vaccine candidates for both adult and pediatric populations. Its pipeline includes multiple vaccine programs at various development stages targeting significant public health needs.